Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
COX-2/5-LOX Inhibitor
Tebufelone is a selective dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO). It exhibits significant anti-inflammatory, analgesic, and antipyretic properties, making it useful for research into inflammatory pathways. This compound is valuable for studying the roles of COX-2 and 5-LO in various biological processes and assessing novel therapeutic strategies for inflammatory diseases. -
Dual COX/5-LOX Inhibitor
ER-34122 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO). This compound exhibits significant anti-inflammatory activity, making it valuable for research into inflammation-related pathways. ER-34122 is particularly relevant for studies investigating the interplay between COX and 5-LO pathways in various disease models and therapeutic contexts. -
5-LO/PGE2 Inhibitor
Canniprene is a potent inhibitor of 5-lipoxygenase (5-LO) and cyclooxygenase/microsomal prostaglandin E2 synthase (PGE2), with IC50 values of 0.4 μM and 10 μM, respectively. Derived from Cannabis sativa, Canniprene modifies the biosynthesis of inflammatory eicosanoids and prostaglandins, making it a valuable tool for researching inflammation and related pathways. Its unique mechanism of action positions Canniprene as a potential candidate for studying inflammatory diseases and therapeutic interventions targeting lipid mediators. -
TXA2/5-Lipoxygenase Inhibitor
CV-6504 is a dual inhibitor targeting thromboxane A2 (TXA2) synthase and 5-lipoxygenase. This compound demonstrates significant biological activity by scavenging reactive oxygen species (ROS) and exhibiting antitumor properties. CV-6504 is applicable in research focused on cancer, inflammation, and cardiovascular diseases, providing valuable insights into therapeutic strategies and molecular mechanisms. -
5-Lipoxygenase/Thromboxane Synthase Inhibitor
E 3040 is an orally active inhibitor of both 5-lipoxygenase and thromboxane synthase, key enzymes involved in inflammatory processes. This dual inhibition provides significant anti-inflammatory activity, making E 3040 a valuable reagent for research into inflammatory diseases and related pathways. Its unique mechanism can facilitate studies on the modulation of leukotrienes and thromboxanes in various biological contexts. -
PDE2 Inhibitor
ND-7001 is a potent inhibitor of phosphodiesterase 2 (PDE2) with an IC50 value of 0.05 μM, demonstrating significant selectivity against PDE3 and PDE4. This compound effectively elevates cGMP levels in primary neuronal cultures derived from rat cerebral cortical neurons, contributing to its role in modulating neuronal signaling. ND-7001 is primarily utilized in research focused on anxiety disorders and neuropharmacology, highlighting its potential for evaluating anxiolytic mechanisms. -
5-LO/TXA2 Inhibitor
E-6700 is a potent inhibitor of 5-lipoxygenase (5-LO) and thromboxane A2 (TXA2) synthetase, with IC50 values of 16.3 μM and 0.026 μM, respectively. This compound effectively inhibits the production of leukotriene B4 (LTB4) and thromboxane B2 (TXB2). E-6700 is suitable for applications in anti-inflammatory research, providing a valuable tool for investigating pathways associated with inflammatory responses. -
KRAS-PDEδ Interaction Inhibitor
Atrovastatin-PEG3-FITC is a KRAS-PDEδ interaction inhibitor that serves as a valuable tool in the study of KRAS signaling pathways. This compound can function as a ligand in fluorescence anisotropy assays, enabling researchers to investigate protein-protein interactions and their implications in cancer biology. Its application aids in understanding the role of KRAS in various malignancies and exploring potential therapeutic interventions. -
MAO A Inhibitor
MD 770222 is a selective and reversible inhibitor of monoamine oxidase A (MAO A). As a major O-demethyl metabolite of Cimoxatone, it exhibits notable inhibitory activity, albeit with reduced potency compared to its parent compound. This reagent is valuable in research focused on neurotransmitter modulation, neuropsychiatric disorders, and the understanding of MAO A's role in various biological processes. -
Lipoxygenase Inhibitor
Umbelliprenin is a prenylated coumarin that functions as a lipoxygenase inhibitor. It exhibits significant antioxidant properties along with anticancer, anti-inflammatory, and immunomodulatory activities. This compound effectively suppresses nitric oxide production in inflammatory macrophages, as well as inhibiting the expression of inducible nitric oxide synthase (iNOS). Umbelliprenin holds promise for research applications in the fields of inflammation, cancer biology, and immunology. -
α-Glucosidase Inhibitor
Isosojagol is an α-Glucosidase inhibitor with an IC50 of 32.2 μM, demonstrating significant potential in modulating carbohydrate metabolism. Isolated from the roots of Dolichos trilobus, Isosojagol exhibits anti-inflammatory properties by inhibiting LPS-induced nitric oxide production in RAW264.7 cells. This reagent is relevant for research into fracture healing, soft tissue injuries, and rheumatoid arthritis, providing a valuable tool for understanding the underlying biological mechanisms. -
IDO1 Inhibitor
VS-15 is an IDO1 inhibitor that selectively binds to the heme-free form of IDO1, interrupting its enzymatic activity. This compound has been linked to the reduction of nitric oxide (NO) production, suggesting additional broad-spectrum inhibitory effects on iNOS. VS-15 is primarily utilized in research focused on immunomodulation and cancer therapy, making it a valuable tool for studies investigating the role of tryptophan metabolism in immune responses. -
5-LO/mPGES-1 Inhibitor
5-LO/mPGES1-IN-1 is a dual inhibitor of 5-lipoxygenase (5-LO) and microsomal prostaglandin E2 synthase-1 (mPGES-1), exhibiting IC50 values of 0.3 μM and 0.4 μM, respectively. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research in inflammatory pathways. Applications include studies focused on the modulation of inflammatory responses, providing insights into potential therapeutic strategies for related diseases. -
TrxR2 Inhibitor
TrxR2-IN-1 is a selective inhibitor of thioredoxin reductase 2 (TrxR2) with an IC50 value of 0.83 μM. This compound accumulates in mitochondria, disrupts mitochondrial function and membrane potential, and enhances reactive oxygen species (ROS) production. It activates ASK1-mediated caspase-dependent apoptosis, induces G2/M cell cycle arrest, and reduces cancer cell migration. TrxR2-IN-1 is valuable for investigating hepatocellular carcinoma and related apoptotic pathways in cancer research. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-2 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). This benzothiophen-2-yl pyrazole carboxylic acid derivative demonstrates significant analgesic and anti-inflammatory properties, exhibiting COX-2 inhibitory activity with an IC50 of 0.01 μM and 5-LOX inhibitory activity with an IC50 of 1.78 μM. COX-2/5-LOX-IN-2 is a valuable tool for research applications aimed at understanding and modulating inflammatory pathways. -
CO/5-LO Inhibitor
P-8977 is a potent dual inhibitor of cyclooxygenase (CO) and 5-lipoxygenase (5-LO) with an IC50 of 0.01 µM and 0.53 µM, respectively. This compound exhibits significant anti-inflammatory activity, demonstrated by its ability to reduce ear edema. P-8977 is valuable for research focused on inflammatory skin conditions and their underlying biochemical mechanisms. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-5 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX). This compound effectively attenuates lipopolysaccharide-induced NF-κB activation in RAW 264.7 macrophages, highlighting its role in modulating inflammatory responses. COX-2/15-LOX-IN-5 exhibits significant anti-inflammatory and antioxidant properties, making it a valuable tool for research into inflammatory diseases and other related biological processes. -
Lipoxygenase/COX Inhibitor
SKF-105809 is a dual inhibitor of lipoxygenase and cyclooxygenase (COX), targeting key enzymes involved in the inflammatory pathway. This compound demonstrates a significant reduction in edema and inflammatory cell infiltration in murine models of ear, paw, and peritoneal inflammation. Additionally, SKF-105809 reduces the production of acute-phase reactive proteins in models of arthritis and exhibits analgesic effects in abdominal contraction assays while preventing ulceration. Its applications extend to the study of inflammatory and immune system disorders, including peritonitis and arthritis. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-1 is a dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX), exhibiting IC50 values of 10.65 μM for COX-1, 0.075 μM for COX-2, and 2.98 μM for 15-LOX. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its ability to modulate key enzymes involved in arachidonic acid metabolism positions COX-2/15-LOX-IN-1 as a promising candidate for therapeutic investigation in inflammatory conditions. -
5-LOX/COX-1 Inhibitor
Atractylochromene is a dual inhibitor targeting 5-lipoxygenase (5-LOX) and cyclooxygenase-1 (COX-1), exhibiting IC50 values of 0.6 μM and 3.3 μM, respectively. This compound serves as a valuable tool in research related to inflammatory pathways and can facilitate the study of related conditions influenced by leukotrienes and prostaglandins. Its inhibitory effects position Atractylochromene as a potential candidate for therapeutic exploration in inflammatory diseases. -
XO/COX/LOX Inhibitor
XO/COX/LOX-IN-1 is a potent inhibitor of xanthine oxidase, cyclooxygenases, and lipoxygenases. This compound exhibits significant anti-inflammatory activity, making it valuable for research in inflammation, cancer, and metabolic diseases. Its multifaceted inhibition profile positions XO/COX/LOX-IN-1 as a critical tool for exploring pathways involved in these pathological conditions. -
COX-2/LOX Inhibitor
COX-2/5-LOX-IN-4 is a potent dual inhibitor targeting both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), with IC50 values of 0.05 μM and 0.003 μM, respectively. By disrupting the arachidonic acid metabolism pathway, this compound effectively decreases the synthesis of prostaglandins and leukotrienes, leading to reduced inflammatory responses. In vivo studies using a rat ear edema model demonstrate its substantial anti-inflammatory activity, with intravenous doses resulting in up to 44% reduction in edema. COX-2/5-LOX-IN-4 is an important tool for investigating the mechanisms underlying inflammatory diseases. -
FAAH/COX Inhibitor
Carpro-AM1 is a dual-acting inhibitor targeting fatty acid amide hydrolase (FAAH) and selectively inhibiting cyclooxygenase (COX) enzymes. This compound exhibits an IC50 value of 94 nM for FAAH, demonstrating significant biological activity in regulating endocannabinoid signaling. Carpro-AM1 is suited for research applications focusing on pain management, inflammation, and the modulation of the endocannabinoid system. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-7 is a selective dual inhibitor targeting cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX) with IC50 values of 0.022 and 1.19 μM, respectively. It also demonstrates inhibition of COX-1 with an IC50 of 28.081 μM. This compound exhibits low cytotoxicity in human colorectal cancer cell lines (HT-29 and HCT116) with IC50 values exceeding 100 μM, and shows a non-ulcerogenic profile. COX-2/15-LOX-IN-7 is valuable for cancer research applications, facilitating the study of inflammatory pathways and therapeutic interventions. -
COX/5-LOX Inhibitor
CI-986 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), effectively preventing coronary vasoconstriction and the excessive production of leukotrienes, including LTB4 and LTC4. This compound exhibits notable anti-inflammatory and analgesic properties, making it a valuable tool for research into inflammation and cardiovascular diseases, including conditions like arthritis. CI-986's unique mechanism positions it as an important reagent in studies focused on the modulation of inflammatory pathways and vascular health. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-1 is a dual inhibitor targeting cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), represented as a benzothiophen-2-yl pyrazole carboxylic acid derivative. This compound exhibits significant analgesic and anti-inflammatory properties, demonstrating enhanced efficacy compared to traditional nonsteroidal anti-inflammatory drugs. COX-2/5-LOX-IN-1 displays potent inhibition of COX-1, COX-2, and 5-LOX, with IC50 values of 12.13, 0.4, and 4.96 μM, respectively, making it a valuable tool for research in pain and inflammation pathways. -
COX-2/5-LOX Inhibitor
Speranskoside is a dual inhibitor of cyclooxygenase-2 (COX-2) and lipoxygenase-15 (5-LOX), exhibiting an IC50 of 2.62 μg/mL for COX-2 and 5.51 μg/mL for 5-LOX. This compound demonstrates significant anti-inflammatory activity, making it valuable for the investigation of gastric ulcers and related disorders. Its unique mechanism of action provides a foundational tool for research into inflammatory pathways and therapeutic interventions. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-3 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and lipoxygenase (5-LOX), exhibiting IC50 values of 45.73 µM for COX-1, 5.45 µM for COX-2, and 4.33 µM for 5-LOX. This compound is valuable for studying inflammatory diseases, as it effectively modulates the associated biochemical pathways. Its dual inhibition may provide insights into the complex roles of COX-2 and 5-LOX in mediating inflammatory responses. -
5-lipoxygenase Inhibitor
L-651896 is a potent inhibitor of 5-lipoxygenase, exhibiting significant anti-inflammatory and antiproliferative properties. By obstructing the production of leukotrienes and prostaglandins, L-651896 is useful in investigating skin diseases and various other inflammatory conditions. Its mechanism of action supports research aimed at understanding the role of lipid mediators in inflammatory pathways. -
5-lipoxygenase/ cyclooxygenase Inhibitor
PD 127443 is an inhibitor of both 5-lipoxygenase and cyclooxygenase, targeting critical enzymes involved in the inflammatory response. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research applications focused on understanding the mechanisms of inflammation and exploring potential therapeutic interventions in inflammatory diseases. -
COX/5-LOX Inhibitor
ZLJ-6 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), demonstrating potent oral bioactivity. With IC50 values of 0.73 μM for COX-1, 0.31 μM for COX-2, and 0.99 μM for 5-LOX, ZLJ-6 exhibits significant anti-inflammatory and analgesic properties. This compound is suitable for research applications aimed at investigating inflammatory pathways and potential therapeutic interventions. -
5-LOX/COX Inhibitor
(-)-Bornyl ferulate serves as a dual inhibitor of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), displaying IC50 values of 10.4 μM and 12.0 μM, respectively. This compound demonstrates significant anti-inflammatory potential, making it useful for research focused on inflammation-related pathways and conditions. Its ability to modulate leukotriene and prostaglandin synthesis positions it as a valuable tool in the study of various inflammatory diseases and therapeutic interventions. -
CypD Inhibitor
CypD-IN-4 is a potent and selective inhibitor of cyclophilin D (CypD), exhibiting high affinity with an IC50 of 0.057 μM. This compound is valuable in researching various conditions related to oxidative stress, neurodegenerative diseases, liver dysfunction, aging processes, autophagy, and diabetes. CypD-IN-4 facilitates the exploration of CypD's role in these pathologies, providing insights into potential therapeutic strategies. -
CypD Inhibitor
CypD-IN-3 is a potent and selective inhibitor of cyclophilin D (CypD), demonstrating high affinity with an IC50 value of 0.01 μM. This compound is valuable for studying a range of biological processes and diseases, including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy, and diabetes. Its specificity towards CypD makes it an important tool for elucidating the role of this target in various cellular functions and pathological conditions. -
CypE Inhibitor
CypE-IN-1 is a highly potent and selective inhibitor of cyclophilin E (CypE), exhibiting an IC50 of 0.013 μM and a Ki value of 0.072 μM. This compound is valuable for investigating the role of CypE in various pathological conditions, including oxidative stress, neurodegenerative diseases, liver disorders, aging processes, autophagy, and diabetes. Researchers can utilize CypE-IN-1 to explore therapeutic strategies targeting CypE-related pathways. -
11β-HSD1 Inhibitor
INCB13739 is a selective and potent inhibitor of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1), exhibiting an IC50 of 3.2 nM in enzymatic assays and 1.1 nM in peripheral blood mononuclear cells (PBMC). This compound demonstrates significant potential for research in type 2 diabetes mellitus (T2DM) and obesity, targeting the regulation of glucocorticoid metabolism, which plays a critical role in metabolic conditions. Its tissue-specific action makes it a valuable tool for understanding 11β-HSD1-related pathways in metabolic disorders. -
Factor Xa Inhibitor
DPC423 free base is a selectively potent Factor Xa inhibitor, demonstrating inhibition constants (Kis) of 0.15 nM in humans and 0.3 nM in rabbits. It exhibits moderate selectivity with Kis of 60 nM against human trypsin, 61 nM against plasma kallikrein, and 6000 nM against thrombin. By inhibiting the formation of the prothrombinase complex, DPC423 reduces thrombin generation, thereby obstructing fibrin formation and platelet activation. This compound is valuable for research applications related to anticoagulation in arterial thrombosis. -
Heme Oxygenase Inhibitor
Zn(II) Deuteroporphyrin IX 2,4 bis ethylene glycol is a potent inhibitor of heme oxygenase (HO), a key enzyme involved in the degradation of heme to bilirubin. By inhibiting HO activity, this compound can effectively reduce the release of hypothalamic hormones such as arginine vasopressin (AVP), oxytocin (OT), and atrial natriuretic peptide (ANP) under hyperosmotic conditions. Its application extends to research involving hyperbilirubinemia and the physiological implications of HO modulation. -
AHR Inhibitor
IK-175 is a selective aryl hydrocarbon receptor (AHR) inhibitor that prevents the translocation of AHR from the cytoplasm to the nucleus. This compound exhibits high specificity for AHR, distinguishing itself from other receptors, transporters, and kinases. IK-175 is primarily used in research applications focused on studying AHR-related pathways and their implications in various diseases, including cancer and immune responses. -
AHR Inhibitor
KYN-101 is a selective AHR inhibitor that is potent and orally active. This compound effectively reduces CYP1A1 mRNA expression, contributing to its role in mediating anti-cancer activity. Researchers can utilize KYN-101 to investigate the therapeutic potential in cancer biology and the modulation of AHR-related signaling pathways. -
AhR activator/Thyroid hormone synthesis and Dopamine beta-hydroxylase inhibitor
2-Mercaptobenzothiazole is an activator of the aryl hydrocarbon receptor (AhR), functioning as an inhibitor of thyroid hormone synthesis and dopamine beta-hydroxylase activity. This compound promotes the invasion of bladder cancer cells by activating AhR transcription and upregulating the expression of CYP1A1 and CYP1B1, implicated in carcinogenesis. Additionally, 2-Mercaptobenzothiazole exhibits inhibition of thyroid peroxidase activity with an IC50 of 11.5 μM and induces significant histological changes in Xenopus laevis, including delayed metamorphosis. It also increases chromosomal aberrations in Chinese hamster ovary cells and inhibits norepinephrine synthesis in murine models, demonstrating its relevance in carcinogenic studies and neurobiological research. -
hCYP1B1 Inhibitor
hCYP1B1-IN-2 is a highly selective inhibitor of the human cytochrome P450 1B1 enzyme (hCYP1B1). It demonstrates remarkable potency in inhibiting hCYP1B1 activity, with an IC50 value of 0.040 nM, alongside a Ki value of 21.71 pM, indicating effective mixed inhibition. This compound also effectively disrupts aryl hydrocarbon receptor (AhR) transcription activities, making it a valuable tool for research applications focused on cancer and toxicology. -
AHR Inhibitor
AHR-IN-1 is a selective aryl hydrocarbon receptor (AHR) inhibitor, exhibiting an IC50 of less than 0.5 μM. This compound is useful for investigating the role of AHR in various biological processes, including immune response modulation and xenobiotic metabolism. AHR-IN-1 serves as a valuable tool for researchers studying the mechanisms by which AHR influences cellular signaling and gene expression. -
hCYP1B1 Inhibitor
CYP1B1-IN-10 is a potent and selective inhibitor of human cytochrome P450 1B1 (hCYP1B1), exhibiting an IC50 value of 0.11 μM. This compound plays a significant role in the investigation of hormone-dependent tumors, including breast and ovarian cancers. Its specificity makes it a valuable tool for studying the therapeutic potential in oncology research. -
COX/5-LOX Inhibitor
Phenethyl ferulate is a potent inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), displaying IC50 values of 4.35 μM and 5.75 μM, respectively. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research into inflammation-related pathways. Its ability to modulate these key enzymes positions it as a promising candidate for studies focused on inflammatory diseases and therapeutic interventions. -
5-LOX/COX Inhibitor
FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), exhibiting IC50 values of 3.5 μM and 3.1 μM, respectively, in RBL-1 cells. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its dual inhibition of leukotriene and prostaglandin synthesis positions FPL 62064 as a pertinent reagent for studies focusing on inflammation and related therapeutic interventions. -
Carbonic anhydrase inhbitor
Indisulam (E7070) is a carbonic anhydrase inhbitor, is also a novel synthetic sulfon-amide that targets the G1 phase of the cell cycle.
